Substance Use Disorder Medication Flexibilities During COVID-19

May 4, 2020

On March 23, 2020, The Department of Healthcare Services (DHCS) received approval of a federal waiver allowing specific flexibilities related to the coronavirus disease 2019 (COVID-19) public health emergency. To facilitate compliance and adherence of medication assisted treatment for substance use disorder (SUD) during the stay-at-home and physical distancing mandates, effective immediately, DHCS is suspending the 30-day supply limitation for medications used in the treatment of SUD, including buprenorphine-containing products. This policy change is only for those buprenorphine-containing medications FDA approved for treatment of SUD. The full policy document is published on the DHCS COVID-19 webpage at the following link: This temporary policy change is effective immediately and remains in effect until further notice.